Updated on 2025/03/28

写真a

 
SANO Tomoyasu
 
Organization
Nagoya University Hospital Urology Lecturer of hospital
Title
Lecturer of hospital

Degree 1

  1. M.D. (Doctor of Medicine) ( 2008.4   Kagawa University ) 

 

Papers 20

  1. Real-world outcomes with avelumab plus axitinib in patients with advanced renal cell carcinoma in Japan: subgroup analyses from the J-DART2 study by International Metastatic Renal Cell Carcinoma Database Consortium risk classification Open Access

    Furukawa, J; Kato, T; Yamasaki, T; Monji, K; Tanaka, T; Tsuchiya, N; Miyagawa, T; Yaegashi, H; Sano, T; Karashima, T; Fujita, K; Hori, J; Ito, T; Kajita, M; Tomita, Y; Shinohara, N; Eto, M; Oya, M; Uemura, H

    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY     2025.2

     More details

    Publisher:International Journal of Clinical Oncology  

    Background: Avelumab + axitinib was approved for the treatment of advanced renal cell carcinoma (aRCC) in Japan in December 2019. We report long-term real-world subgroup analyses with first-line avelumab + axitinib in patients with aRCC by International Metastatic RCC Database Consortium (IMDC) risk classification from the J-DART2 study in Japan. Methods: J-DART2 was a multicenter, noninterventional, retrospective study examining characteristics, treatment patterns, and outcomes in patients with aRCC who started first-line avelumab + axitinib in Japan between December 2019 and October 2022. Results: Data from 150 patients across 19 sites were analyzed. IMDC risk was favorable in 39 patients (26.0%), intermediate (1 risk factor) in 46 (30.7%), intermediate (2 risk factors) in 36 (24.0%), and poor in 29 (19.3%). Baseline characteristics were generally consistent across IMDC risk subgroups. In subgroups with favorable, intermediate (1 risk factor), intermediate (2 risk factors), and poor risk, median progression-free survival was 31.0, 15.3, 16.4, and 8.1 months; median overall survival (OS) was not reached, but 24-month OS rates were 95.2%, 91.3%, 85.3%, and 57.6%, respectively. Objective response rates were 54.5%, 56.8%, 47.1%, and 54.2%, respectively. High-dose corticosteroid treatment for immune-related adverse events was administered in 5.1%, 8.7%, 8.3%, and 6.9% of patients, respectively. Conclusion: Subgroup analyses from J-DART2 confirm the long-term real-world effectiveness of first-line avelumab + axitinib across IMDC risk groups in patients with aRCC in Japan. Our findings were consistent with previous analyses by IMDC risk and support the favorable benefit-risk profile of avelumab + axitinib in clinical practice in Japan.

    DOI: 10.1007/s10147-024-02655-4

    Open Access

    Web of Science

    Scopus

    PubMed

  2. Impact of lymph node dissection during surgery on the efficacy of pembrolizumab in patients with metastatic urothelial carcinoma

    Kanno, T; Ito, K; Kita, Y; Mochizuki, T; Sano, T; Yokomizo, A; Abe, T; Tsuchihashi, K; Tatarano, S; Inokuchi, J; Takahashi, A; Matsui, Y; Nishiyama, H; Kitamura, H; Saito, R; Kobayashi, T

    INTERNATIONAL JOURNAL OF UROLOGY     2025.2

     More details

    Publisher:International Journal of Urology  

    Objectives: The impact of lymph node dissection (LND) on the efficacy of pembrolizumab in patients with urothelial carcinoma (UC) who develop metastasis after surgery remains unclear. This study aimed to investigate the efficacy of pembrolizumab in patients with metastatic UC who underwent primary tumor resection with LND. Patients and methods: This retrospective study included patients who initially underwent radical surgery with or without LND for non-metastatic UC and later received pembrolizumab for recurrent lesions. Data were collected from a retrospective nationwide Japanese cohort study in patients with metastatic UC treated with pembrolizumab. The primary endpoints were overall response rate (ORR) and overall survival (OS). Multivariate analysis was performed to identify predictors of OS. Results: A total of 393 patients (273 [69.5%] underwent LND, and 120 (30.5%) did not) were included in this study. The ORRs for patients with and without LND were 30.8% and 27.3%, respectively (p = 0.460). No significant difference in OS was observed between the two groups (p = 0.471). Multivariate Cox regression analysis revealed that a neutrophil-to-lymphocyte ratio ≥3.0, Eastern Cooperative Oncology Group performance status ≥2, hemoglobin <11, and liver metastasis were associated with worse OS. However, LND was not associated with OS. Conclusions: LND during primary tumor resection did not affect the efficacy of pembrolizumab in patients with metastatic UC.

    DOI: 10.1111/iju.70002

    Web of Science

    Scopus

    PubMed

  3. J-AVENUE: A retrospective, real-world study evaluating patient characteristics and outcomes in patients with advanced urothelial carcinoma treated with avelumab first-line maintenance therapy in Japan Open Access

    Kikuchi E., Hayakawa N., Nakayama M., Uno M., Nakatsu H., Kitagawa C., Miyake H., Yamada T., Fujita K., Shimoyama H., Nishihara K., Kobayashi M., Nakamura M., Fujimoto K., Sano T., Nishiyama N., Ito T., Kajita M., Kobayashi T., Kitamura H.

    International Journal of Urology   Vol. 31 ( 8 ) page: 859 - 867   2024.8

     More details

    Publisher:International Journal of Urology  

    Objectives: The JAVELIN Bladder 100 phase 3 trial showed that avelumab first-line maintenance + best supportive care significantly prolonged overall survival and progression-free survival versus best supportive care alone in patients with advanced urothelial carcinoma who were progression-free following first-line platinum-based chemotherapy. We report findings from J-AVENUE (NCT05431777), a real-world study of avelumab first-line maintenance therapy in Japan. Methods: Medical charts of patients with advanced urothelial carcinoma without disease progression following first-line platinum-based chemotherapy, who received avelumab maintenance between February and November 2021, were reviewed. Patients were followed until June 2022. The primary endpoint was patient characteristics; secondary endpoints included time to treatment failure and progression-free survival. Results: In 79 patients analyzed, median age was 72 years (range, 44–86). Primary tumor site was upper tract in 45.6% and bladder in 54.4%. The most common first-line chemotherapy regimen was cisplatin + gemcitabine (63.3%). Median number of chemotherapy cycles received was four. Best response to chemotherapy was complete response in 10.1%, partial response in 58.2%, and stable disease in 31.6%. Median treatment-free interval before avelumab was 4.9 weeks. With avelumab first-line maintenance therapy, the disease control rate was 58.2%, median time to treatment failure was 4.6 months (95% CI, 3.3–6.4), and median progression-free survival was 6.1 months (95% CI, 3.6–9.7). Conclusions: Findings from J-AVENUE show the effectiveness of avelumab first-line maintenance in patients with advanced urothelial carcinoma in Japan in clinical practice, with similar progression-free survival to JAVELIN Bladder 100 and previous real-world studies, supporting its use as a standard of care.

    DOI: 10.1111/iju.15473

    Open Access

    Scopus

  4. Synthetic retinoid-mediated preconditioning of cancer-associated fibroblasts and macrophages improves cancer response to immune checkpoint blockade Open Access

    Owaki, T; Iida, T; Miyai, Y; Kato, K; Hase, T; Ishii, M; Ando, R; Hinohara, K; Akashi, T; Mizutani, Y; Ishikawa, T; Mii, S; Shiraki, Y; Esaki, N; Yamamoto, M; Tsukamoto, T; Nomura, S; Murakami, T; Takahashi, M; Yuguchi, Y; Maeda, M; Sano, T; Sassa, N; Matsukawa, Y; Kawashima, H; Akamatsu, S; Enomoto, A

    BRITISH JOURNAL OF CANCER   Vol. 131 ( 2 ) page: 372 - 386   2024.7

     More details

    Publisher:British Journal of Cancer  

    Background: The proliferation of cancer-associated fibroblasts (CAFs) hampers drug delivery and anti-tumor immunity, inducing tumor resistance to immune checkpoint blockade (ICB) therapy. However, it has remained a challenge to develop therapeutics that specifically target or modulate CAFs. Methods: We investigated the involvement of Meflin+ cancer-restraining CAFs (rCAFs) in ICB efficacy in patients with clear cell renal cell carcinoma (ccRCC) and urothelial carcinoma (UC). We examined the effects of Am80 (a synthetic retinoid) administration on CAF phenotype, the tumor immune microenvironment, and ICB efficacy in cancer mouse models. Results: High infiltration of Meflin+ CAFs correlated with ICB efficacy in patients with ccRCC and UC. Meflin+ CAF induction by Am80 administration improved ICB efficacy in the mouse models of cancer. Am80 exerted this effect when administered prior to, but not concomitant with, ICB therapy in wild-type but not Meflin-deficient mice. Am80-mediated induction of Meflin+ CAFs was associated with increases in antibody delivery and M1-like tumor-associated macrophage (TAM) infiltration. Finally, we showed the role of Chemerin produced from CAFs after Am80 administration in the induction of M1-like TAMs. Conclusion: Our data suggested that Am80 administration prior to ICB therapy increases the number of Meflin+ rCAFs and ICB efficacy by inducing changes in TAM phenotype. (Figure presented.)

    DOI: 10.1038/s41416-024-02734-3

    Open Access

    Web of Science

    Scopus

    PubMed

  5. Combined use of tyrosine kinase inhibitors with PD-(L)1 blockade increased the risk of thyroid dysfunction in PD-(L)1 blockade: a prospective study Open Access

    Kobayashi, T; Iwama, S; Yamagami, A; Izuchi, T; Suzuki, K; Otake, K; Yasuda, Y; Ando, M; Onoue, T; Miyata, T; Sugiyama, M; Hagiwara, D; Suga, H; Banno, R; Hase, T; Nishio, N; Mori, S; Shimokata, T; Sano, T; Niimi, K; Yoshikawa, N; Akamatsu, S; Ando, Y; Akiyama, M; Sone, M; Ishii, M; Arima, H

    CANCER IMMUNOLOGY IMMUNOTHERAPY   Vol. 73 ( 8 )   2024.6

     More details

    Publisher:Cancer Immunology, Immunotherapy  

    Background: Anti-programmed cell death-1 (ligand-1) antibody [PD-(L)1-Ab] can cause destructive thyroiditis and/or hypothyroidism. In addition, tyrosine kinase inhibitors (TKIs) frequently induce hypothyroidism. The aim of this prospective study is to examine the incidence and clinical characteristics of thyroid dysfunction induced by combination therapy of a PD-(L)1-Ab and TKI [PD-(L)1-Ab/TKI]. Methods: A total of 757 patients treated with PD-(L)1-Ab or PD-(L)1-Ab/TKI were evaluated for anti-thyroid antibodies (ATAs) at baseline and for thyroid function for 48 weeks after treatment initiation and then observed until the last visit. Results: The cumulative incidences of destructive thyroiditis [4/23 (17.4%) vs. 45/734 (6.1%) patients, p < 0.001], isolated hypothyroidism [10/23 (43.5%) vs. 29/734 (4.0%) patients, p < 0.001], and all thyroid dysfunction [14/23 (60.9%) vs. 74/734 (10.1%) patients, p < 0.001] were significantly higher in the PD-(L)1-Ab/TKI group than PD-(L)1-Ab group, respectively. All patients positive for ATAs at baseline developed thyroid dysfunction after PD-(L)1-Ab/TKI treatment, a significantly higher incidence than that in those negative for ATAs at baseline [4/4 (100%) vs. 10/19 (52.6%) patients, p = 0.026]. Conclusions: The addition of TKIs increased the risk of thyroid dysfunction induced by PD-(L)1-Ab, with the risk being higher in patients positive for baseline ATAs.

    DOI: 10.1007/s00262-024-03733-2

    Open Access

    Web of Science

    Scopus

    PubMed

  6. Impact of the coronavirus disease 2019 pandemic on the number of undergoing radical nephroureterectomy and postoperative adjuvant systematic therapy for upper tract urothelial carcinomas in Japan: A multicenter retrospective study

    Tsuruta, K; Majima, T; Nishikimi, T; Kashima, A; Soeda, Y; Inoue, S; Sano, T; Maeda, M; Yamamoto, A; Kobayashi, I; Kajikawa, K; Matsukawa, Y; Kato, M; Tsuzuki, T; Sassa, N

    INTERNATIONAL JOURNAL OF UROLOGY   Vol. 30 ( 5 ) page: 464 - 471   2023.5

     More details

    Publisher:International Journal of Urology  

    Objectives: The coronavirus disease 2019 pandemic has affected cancer management worldwide. For upper tract urothelial carcinomas, delays in treatments are not recommended even during the pandemic. We investigated the impact of the pandemic on patients with these carcinomas who underwent radical nephroureterectomy (RNU) and adjuvant systematic therapy before and after COVID-19 spread in Japan. Methods: This multicenter retrospective study included 304 patients who underwent RNU for upper tract urothelial carcinomas between May 1, 2019, and December 31, 2021, in Aichi, Japan. The patients were categorized into three groups based on whether they underwent surgery in the prepandemic (before infection spread in Japan), early pandemic (between confirmation of the first case and vaccination initiation), and late pandemic (after the start of vaccination in Japan) phases. The patient characteristics, diagnostic methods, pathological findings, and postoperative therapy were compared among the three phases. Results: Overall, 74, 152, and 78 patients underwent RNU in the prepandemic, early pandemic, and late pandemic phases, respectively. The number of patients who underwent preoperative ureteroscopy decreased significantly from the prepandemic phase to the late pandemic phase due to pandemic-related restrictions (p = 0.016). There was no difference in the time to the first visit or pathological findings. Among patients classified as high-risk according to existing clinical trials, the proportion receiving adjuvant systematic therapy after RNU decreased significantly from 52.3% to 19% (p = 0.003). Conclusions: There was no difference in the pathological findings. The number of patients receiving appropriate adjuvant systematic therapy decreased during the pandemic.

    DOI: 10.1111/iju.15157

    Web of Science

    Scopus

    PubMed

  7. The usefulness of meflin expression in cancer-associated fibroblasts as a predictive marker for immune checkpoint inhibitor in clear cell renal cell carcinoma.

    Owaki, T; Miyai, Y; Naito, Y; Sano, T; Enomoto, A

    JOURNAL OF CLINICAL ONCOLOGY   Vol. 41   2023.2

     More details

  8. Clinical practice pattern in patients with advanced urothelial cancer who had progressed on pembrolizumab in the pre-enfortumab vedotin era

    Kita, Y; Ito, K; Sano, T; Hashimoto, K; Mochizuki, T; Shiraishi, Y; Araki, H; Fujiwara, M; Kanamaru, S; Takahashi, T; Hishiki, K; Okada, T; Ogawa, K; Ito, M; Kojima, T; Nishiyama, N; Matsui, Y; Nishiyama, H; Kitamura, H; Kobayashi, T

    INTERNATIONAL JOURNAL OF UROLOGY   Vol. 29 ( 7 ) page: 647 - 655   2022.7

     More details

    Publisher:International Journal of Urology  

    Objectives: Pembrolizumab, an anti-PD-1 monoclonal antibody, revolutionized the treatment for advanced urothelial carcinoma. However, the standard treatment for patients after disease progression with pembrolizumab had not been established until the recent approval of enfortumab vedotin. We analyzed the treatment of these patients in the real world, and the patient background and outcomes. Methods: We extracted data from 543 patients who experienced progressive disease after pembrolizumab initiation from a Japanese nation-wide cohort of platinum-refractory, metastatic urothelial carcinoma. Results: The median overall survival of the 543 patients was 3.5 months (95% confidence interval 3.0–4.1). Of these, only 20.6% (n = 112) received chemotherapy as a subsequent systemic treatment after progressive disease. The regimen of chemotherapy was very diverse. The median overall survival was 11.9 months (95% confidence interval 9.2–14.7) for patients who received chemotherapy, compared to 2.4 months for those who did not receive chemotherapy (95% confidence interval 2.1–2.9; P < 0.0001). Patients who received subsequent chemotherapy were more likely to have better performance status, neutrophil-to-lymphocyte ratio <3, hemoglobin >11 mg/dL, and history of a single chemotherapeutic regimen at pembrolizumab initiation. Conclusions: This report highlights the real-world practice of the management after pembrolizumab treatment failure in the pre-enfortumab vedotin era, characterized by infrequent use of subsequent anticancer therapy comprising various regimens, reflecting the lack of a standard treatment. Clinical introduction of enfortumab vedotin is expected to improve treatment outcomes in this setting. The present study will provide important baseline data for evaluating the influence of enfortumab vedotin on clinical practices and outcomes.

    DOI: 10.1111/iju.14861

    Web of Science

    Scopus

    PubMed

  9. pT3 subclassification of renal pelvic cancer considering the tumor location improves the patients' prognostic accuracy

    Sano Tomoyasu, Kato Masashi, Sassa Naoto, Sadachi Ryo, Hirakawa Akihiro, Kamihira Osamu, Hirabayashi Tsuyoki, Nishikimi Toshinori, Katsuno Satoshi, Kimura Toru, Hattori Ryohei, Gotoh Momokazu, Tsuzuki Toyonori

    VIRCHOWS ARCHIV     2021.1

     More details

    Publisher:Virchows Archiv  

    DOI: 10.1007/s00428-020-02973-8

    Web of Science

    Scopus

  10. Grade group 2 (10% >= GP4) patients have very similar malignant potential with grade group 1 patients, given the risk of intraductal carcinoma of the prostate

    Kato Masashi, Hirakawa Akihiro, Sato Hiroyuki, Hanazawa Ryoichi, Naito Yushi, Tochigi Kosuke, Sano Tomoyasu, Ishida Shohei, Funahashi Yasuhito, Fujita Takashi, Matsukawa Yoshihisa, Hattori Ryohei, Tsuzuki Toyonori

    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY     2021.1

     More details

    Publisher:International Journal of Clinical Oncology  

    DOI: 10.1007/s10147-020-01841-4

    Web of Science

    Scopus

  11. Effect of core needle biopsy number on intraductal carcinoma of the prostate (IDC-P) diagnosis in patients with metastatic hormone-sensitive prostate cancer

    Kato Masashi, Hirakawa Akihiro, Kobayashi Yumiko, Yamamoto Akiyuki, Naito Yushi, Tochigi Kosuke, Sano Tomoyasu, Ishida Shohei, Funahashi Yasuhito, Fujita Takashi, Matsukawa Yoshihisa, Hattori Ryohei, Tsuzuki Toyonori

    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY   Vol. 25 ( 12 ) page: 2130 - 2137   2020.12

     More details

    Publisher:International Journal of Clinical Oncology  

    DOI: 10.1007/s10147-020-01756-0

    Web of Science

    Scopus

  12. The clinical benefit of sequential therapy with androgen receptor axis-targeted agents alone in patients with castration-resistant prostate cancer: A propensity score-matched comparison study

    Naito Yushi, Kato Masashi, Kawanishi Hideji, Yuguchi Yuri, Yuba Takuma, Ishikawa Tomohiro, Hattori Kyosuke, Yamamoto Akiyuki, Sano Tomoyasu, Matsukawa Yoshihisa, Kimura Toru, Nishikimi Toshinori, Hattori Ryohei, Tsuzuki Toyonori, Gotoh Momokazu

    PROSTATE   Vol. 80 ( 15 ) page: 1373 - 1380   2020.11

     More details

  13. Propensity score-matched comparison of docetaxel and androgen receptor axis-targeted agents in patients with castration-resistant intraductal carcinoma of the prostate

    Yamamoto Akiyuki, Kato Masashi, Hattori Kyosuke, Naito Yushi, Tochigi Kosuke, Sano Tomoyasu, Kawanishi Hideji, Ishikawa Tomohiro, Yuba Takuma, Hattori Ryohei, Gotoh Momokazu, Tsuzuki Toyonori

    BJU INTERNATIONAL   Vol. 125 ( 5 ) page: 702 - 708   2020.5

     More details

    Publisher:BJU International  

    DOI: 10.1111/bju.14970

    Web of Science

    Scopus

  14. Proposal of a new subcategory of the pT3 classification: Effects of tumor location and subclassification of renal pelvic pT3 to predict the prognosis of pelvic carcinoma more accurately than the current TNM classification

    Sano Tomoyasu, Hattori Ryohei, Yamada Shin, Kamihira Osamu, Kobayashi Hiroaki, Tsuji Yoshikazu, Sassa Naoto, Gotoh Momokazu, Tsuzuki Toyonori

    JOURNAL OF CLINICAL ONCOLOGY   Vol. 38 ( 6 )   2020.2

     More details

  15. Response of intraductal carcinoma of the prostate to androgen deprivation therapy predicts prostate cancer prognosis in radical prostatectomy patients

    Kato Masashi, Hirakawa Akihiro, Kobayashi Yumiko, Yamamoto Akiyuki, Ishida Ryo, Kamihira Osamu, Sano Tomoyasu, Majima Tsuyoshi, Ishida Shohei, Funahashi Yasuhito, Sassa Naoto, Fujita Takashi, Matsukawa Yoshihisa, Hattori Ryohei, Gotoh Momokazu, Tsuzuki Toyonori

    PROSTATE   Vol. 80 ( 3 ) page: 284 - 290   2020.2

     More details

  16. The influence of the presence of intraductal carcinoma of the prostate on the grade group system's prognostic performance

    Kato Masashi, Hirakawa Akihiro, Kobayashi Yumiko, Yamamoto Akiyuki, Ishida Ryo, Sano Tomoyasu, Kimura Tohru, Majima Tsuyoshi, Ishida Shohei, Funahashi Yasuhito, Sassa Naoto, Fujita Takashi, Matsukawa Yoshihisa, Yamamoto Tokunori, Hattori Ryohei, Gotoh Momokazu, Tsuzuki Toyonori

    PROSTATE   Vol. 79 ( 10 ) page: 1065 - 1070   2019.7

     More details

  17. Risk of recurrence in patients with positive surgical margin at apex only versus other locations after radical prostatectomy.

    Kato Masashi, Yamamoto Akiyuki, Ishida Ryo, Kimura Tohru, Sano Tomoyasu, Owaki Takayuki, Sassa Naoto, Gotoh Momokazu, Tsuzuki Toyonori

    JOURNAL OF CLINICAL ONCOLOGY   Vol. 37 ( 7 )   2019.3

     More details

  18. The impact of intraductal carcinoma of the prostate on the grade group system.

    Kato Masashi, Yamamoto Akiyuki, Ishida Ryo, Kimura Tohru, Sano Tomoyasu, Gotoh Momokazu, Tsuzuki Toyonori

    JOURNAL OF CLINICAL ONCOLOGY   Vol. 37 ( 7 )   2019.3

     More details

  19. Comparison of the prognosis between pT3 urothelial carcinoma of the renal pelvis and pT3 urothelial carcinoma of the ureter

    Tsuzuki Toyonori, Sano Tomoyasu, Kato Mashashi, Sassa Naoto, Nishikimi Toshinori, Hattori Ryohei, Gotoh Momokazu

    LABORATORY INVESTIGATION   Vol. 99   2019.3

     More details

  20. Comparison of the prognosis between pT3 urothelial carcinoma of the renal pelvis and pT3 urothelial carcinoma of the ureter

    Tsuzuki Toyonori, Sano Tomoyasu, Kato Mashashi, Sassa Naoto, Nishikimi Toshinori, Hattori Ryohei, Gotoh Momokazu

    MODERN PATHOLOGY   Vol. 32   2019.3

     More details

▼display all